Skip to content
C7C7C7

Drawing based on the label description. No photo yet.

“30 mg, 63020-533-30, round, white, biconvex film-coated tablets with debossed "C7" on one side and plain on the other side, 30 tablets in a wide-mouth white high density polyethylene (HDPE) bottle with a desiccant canister and induction sealed child resistant closure”

C7 pill

Pill with imprint C7 is white, round, 8 mm and has been identified as Ponatinib Hydrochloride 30 mg. It is used for myeloid leukemia. It is supplied by Takeda Pharmaceuticals America, Inc.

Ponatinib Hydrochloride 30 mg

Imprint
C7
Strength
30 mg
Used for
Myeloid leukemia
Color
White
Shape
Round
Size
8 mm
Score
No score line
Form
Tablet, film coated
Manufacturer
Takeda Pharmaceuticals America, Inc
Drug class
Cancer medicine (kinase inhibitor)
NDC
63020-533, 63020-533-30

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Ponatinib Hydrochloride pills and guides

What is Ponatinib Hydrochloride used for?

Ponatinib Hydrochloride is used for myeloid leukemia.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

ICLUSIG® is indicated for the treatment of adult patients with:

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

  • Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
  • As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.

Chronic Myeloid Leukemia (CML)

  • Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors.
  • Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated.
  • T315I-positive CML (chronic phase, accelerated phase, or blast phase).

Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.

From the FDA-approved label on DailyMed (published Aug 19, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • One side shows C7 and the other side is plain.
  • It is white, round, 8 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold under the brand name Iclusig.

Ingredients

Active: Ponatinib Hydrochloride

Inactive: Lactose Monohydrate, Microcrystalline Cellulose, Sodium Starch Glycolate Type B Potato, Silicon Dioxide, Magnesium Stearate

Other pills with imprint C 7

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Ponatinib Hydrochloride pills